ARTICLE | Company News
Idenix, Merck deal
September 1, 2014 7:00 AM UTC
Merck completed its tender offer to acquire Idenix for $24.50 per share in cash, or about $3.9 billion (see BioCentury, June 16). ...
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Merck completed its tender offer to acquire Idenix for $24.50 per share in cash, or about $3.9 billion (see BioCentury, June 16). ...